Holen Sie sich die Stockscreener-App
3.64
1.62%
-0.06
Vorhandelsmarkt:
3.79
0.15
+4.12%
Schlusskurs vom Vortag:
$3.70
Offen:
$3.7
24-Stunden-Volumen:
94,978
Relative Volume:
0.18
Marktkapitalisierung:
$23.29M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-31.97M
KGV:
-0.4406
EPS:
-8.2612
Netto-Cashflow:
$-5.66M
1W Leistung:
-6.43%
1M Leistung:
-46.55%
6M Leistung:
-57.92%
1J Leistung:
-66.06%
1-Tages-Spanne:
$3.52
$3.72
1-Wochen-Bereich:
$3.52
$4.25
52-Wochen-Spanne:
$2.07
$19.12
Quantum Biopharma Ltd Stock (QNTM) Company Profile
Firmenname
Quantum Biopharma Ltd
Sektor
Branche
Telefon
-
Adresse
-
Compare QNTM vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QNTM
Quantum Biopharma Ltd
|
3.64 | 23.67M | 0 | -31.97M | -5.66M | -8.2612 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Quantum Biopharma Ltd Aktie (QNTM) Neueste Nachrichten
QNTM Should I Buy - Intellectia AI
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Proprietary Therapy for MS Treatment - The Globe and Mail
Quantum BioPharma Advances Lucid-MS Therapy for Multiple Sclerosis After Positive Phase 1 Trial - citybuzz -
Quantum BioPharma Ltd. Subordinate Voting Shares - The Canadian Securities Exchange (CSE)
Quantum BioPharma (QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets - Yahoo Finance
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Quantum BioPharma (QNTM) Highlights Lucid-MS and unbuzzd™ Growth Opportunities on BioMedWire Podcast - NewMediaWire
Quantum BioPharma (QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast - Yahoo Finance
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast - TipRanks
Quantum BioPharma Hires Stocks.news for Investor Relations Services in $250,000 Deal - citybuzz -
Quantum BioPharma Advances Multiple Sclerosis Drug Candidate and Alcohol Metabolism Product - citybuzz -
Quantum BioPharma Hit by FDA Clinical Hold on Lead MS Drug as Director Resigns - TipRanks
Quantum BioPharma Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast - citybuzz -
[6-K] Quantum Biopharma Ltd. Current Report (Foreign Issuer) | QNTM SEC FilingForm 6-K - Stock Titan
Quantum BioPharma hires IR Agency for investor relations By Investing.com - Investing.com Australia
Quantum BioPharma Hires Stocks.news IR Agency to Boost Market Visibility - TipRanks
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd. - The Manila Times
Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns - The Manila Times
Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead ... - Caledonian Record
Quantum BioPharma (QNTM) hires Stocks.news in US$250K investor relations push - Stock Titan
Quantum BioPharma Engages Stocks.news For Investor - GlobeNewswire
Quantum BioPharma Ltd. Provides Update on FDA Clinical Hold for Lucid-MS Drug Candidate - Quiver Quantitative
Quantum BioPharma Provides Corporate Update - Toronto Star
QNTM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Quantum Biopharma Ltd. Q4 2025 Earnings: Wider Loss as Pre-Revenue Biotech Navigates Pipeline Progress - thelegaladvocate.com
Quantum BioPharma Advances MS Therapy, Diversifies Pipeline with Wellness Products - citybuzz -
Quantum BioPharma Momentum Surges Amid MS Resarch UpdateQuantum BioPharma (NASDAQ:QNTM) - Benzinga
Quantum Biopharma Ltd. (QNTM) Q4 2025 Earnings: Narrowing Losses Amidst No Revenue DisclosureEPS Surprise History - thelegaladvocate.com
Quantum Biopharma Ltd. (QNTM) Q4 2025 Earnings: Net Loss Deepens as Pre-Revenue Stock Sheds 23.7%Annual Earnings Summary - The League of Women Voters of Texas
QNTM Q4 2025 Earnings: Loss Per Share Reported, Shares Surge on Biotech ProgressTrough Earnings Signal - The Legal Advocate
Quantum Biopharma Ltd. (QNTM) Q4 2025 Earnings: Biotech Reports Wider Loss Amid Strategic Progress, Stock Jumps 18%Certified Trade Ideas - Newser
Quantum Biopharma Ltd. (QNTM) Q4 2025 Earnings: Pre-Revenue Biotech Reports Narrowed Loss, Shares RallyEstimate Accuracy - newsline.com
Quantum BioPharma Reaches Halfway Point in Patient Enrollment in Imaging Study With MGH - Moomoo
Quantum BioPharma (QNTM) Reports Midpoint Enrollment Milestone in MS Imaging Study - NewMediaWire
Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital - Sahm
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Midpoint Enrollment Milestone in MS Imaging Study - TipRanks
Quantum BioPharma (QNTM) Achieves Key Enrollment Milestone in MS Study - GuruFocus
Quantum BioPharma Shares Climb as Multiple Sclerosis Imaging Study Advances (QNTM) - Yahoo Finance
Quantum BioPharma reaches midpoint in MGH MS imaging study - grafa.com
Quantum BioPharma stock surges on MS imaging study progress By Investing.com - Investing.com Australia
Quantum BioPharma stock surges on MS imaging study progress - Investing.com
Quantum BioPharma Hits Midpoint in MGH Imaging Study as Lucid-MS Advances Toward Phase 2 - TipRanks
Quantum BioPharma (NASDAQ: QNTM) advances MS imaging and Lucid-MS plans - Stock Titan
Quantum BioPharma Ltd. Achieves Halfway Point in Collaborative MS Imaging Study with Massachusetts General Hospital - Quiver Quantitative
Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with ... - Enidnews.com
Finanzdaten der Quantum Biopharma Ltd-Aktie (QNTM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):